Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

Retinal Pigment Epithelial Detachment Clinical Trial

Official title:
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.

Status Completed

Clinical Trial Summary

This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Choroidal Neovascularization
Retinal Detachment
Retinal Pigment Epithelial Detachment

Clinical Trial Details

NCT number	NCT00749021
Study type	Interventional
Source	Southern California Desert Retina Consultants, MC
Contact
Status	Completed
Phase	Phase 1
Start date	September 2008
Completion date	August 2012

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01666236` - Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy	Phase 4
Completed	`NCT01628354` - Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration	Phase 4
Terminated	`NCT01189019` - HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration	Phase 2